New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2014
12:55 EDTINSV, INSV, INSVInSite Vision to host conference call
Conference call to discuss late-stage pipeline, phase 3 clinical trial results, and 2014 regulatory plans will be held on January 9 at 1 pm. Webcast Link
News For INSV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
08:37 EDTINSVQLT Inc., InSite Vision agree on amended, restated merger agreement
Subscribe for More Information
August 21, 2015
08:44 EDTINSVQLT Inc. provides update on proposed acquisition of InSite Vision
QLT Inc. announces that it has been advised by InSite Vision that the board of InSite has determined in good faith after consultation with its independent financial and legal advisors that the previously announced unsolicited offer from a multi-national pharmaceutical company to acquire all of the issued and outstanding shares of InSite constitutes a "Company Superior Proposal" as defined in the Agreement and Plan of Merger, dated June 8, by and among Insite, QLT and Isotope Acquisition Corp., as amended and restated. InSite has further advised QLT that InSite intends, subject to QLT's right to match the Proposal, to terminate the Merger Agreement and enter into an agreement with the Bidder to implement the Proposal. Under the Merger Agreement, QLT has the option until 5:00 p.m. PDT on Wednesday, August 26, to negotiate a possible amendment to the terms of the Merger Agreement to match or exceed the Proposal. InSite has advised QLT that it intends to negotiate in good faith with QLT during the Negotiation Period. If at the end of the Negotiation Period such amended QLT proposal results in the Proposal not being a "Company Superior Proposal" under the Merger Agreement, InSite and QLT will enter into an agreement to reflect the amended terms of the transaction. In the event that QLT elects not to match or exceed the Proposal and if InSite terminates the Merger Agreement in order to enter into an agreement with the Bidder, then InSite is required to pay a termination fee to QLT in the amount of $1.17M. QLT is considering its position with respect to the Proposal and its matching right, and will keep the market apprised of further developments.
08:31 EDTINSVInSite Vision says unsolicted offer a 'company superior proposal'
Subscribe for More Information
August 17, 2015
16:12 EDTINSVInSite Vision says FDA accepts BromSite NDA, says satisfies merger condition
InSite Vision (INSV) announced that the U.S. FDA, in a Day-74 letter, has accepted for review InSite's NDA for BromSite, or 0.075% bromfenac. The FDA has assigned a Prescription Drug User Fee Act action date of April 10, 2016. InSite is seeking FDA approval for BromSite in the treatment of inflammation and prevention of ocular pain in the post-cataract surgery setting. BromSite has a patent life extending to August 2029. "The FDA's notification letter is an important milestone for the BromSite NDA and, importantly, satisfies a condition of our merger agreement with QLT (QLTI)," said InSite CEO Timothy Ruane.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use